 AIM ImmunoTech Inc NYSEAMERICAN:AIM announced Monday that it has dosed the first healthy subjects in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for the coronavirus CVOID-19 and other respiratory viral diseases. The current study plans call for the enrollment of eight healthy subjects in each of four Ampligen treatment groups and eight placebo subjects, for a total of 40 healthy subjects, the company said. 